Neurogene Inc.

NasdaqGM:NGNE Stock Report

Market Cap: US$335.4m

Neurogene Management

Management criteria checks 1/4

Neurogene's CEO is Rachel McMinn, appointed in Jan 2018, has a tenure of 6.92 years. total yearly compensation is $1.08M, comprised of 43.3% salary and 56.7% bonuses, including company stock and options. directly owns 8.75% of the company’s shares, worth $29.36M. The average tenure of the management team and the board of directors is 1 years and 1 years respectively.

Key information

Rachel McMinn

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage43.3%
CEO tenure6.9yrs
CEO ownership8.8%
Management average tenureless than a year
Board average tenureless than a year

Recent management updates

Recent updates

Neurogene: Interesting CNS Disease Company, Data Coming Soon

Nov 10

Neurogene Stock: Gene Therapy Specialist May Break Chain Of Failed Mergers

Mar 26

CEO Compensation Analysis

How has Rachel McMinn's remuneration changed compared to Neurogene's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$3m

Jun 30 2024n/an/a

US$2m

Mar 31 2024n/an/a

US$9m

Dec 31 2023US$1mUS$468k

US$14m

Sep 30 2023n/an/a

-US$51m

Jun 30 2023n/an/a

-US$49m

Mar 31 2023n/an/a

-US$52m

Dec 31 2022US$657kUS$448k

-US$55m

Compensation vs Market: Rachel's total compensation ($USD1.08M) is below average for companies of similar size in the US market ($USD2.15M).

Compensation vs Earnings: Rachel's compensation has increased whilst the company is unprofitable.

CEO

Rachel McMinn (51 yo)

6.9yrs

Tenure

US$1,080,629

Compensation

Dr. Rachel L. McMinn, Ph D., is the Founder of Neurogene Inc. and Chief Executive Officer and Executive Chair of Board since December 2023. Dr. McMinn founded Private Neurogene in January 2018 and served a...

Leadership Team

NamePositionTenureCompensationOwnership
Rachel McMinn
Founder6.9yrsUS$1.08m8.75%
$ 29.4m
Christine Cvijic
Presidentless than a yearUS$1.13m0.52%
$ 1.7m
Stuart Cobb
Chief Scientific Officerless than a yearUS$784.32k0.40%
$ 1.3m
Donna Cochener-Metcalfe
Senior VP & General Counselless than a yearno data0.0014%
$ 4.5k
Effie Albanis
Senior Vice President of Early Clinical & Translational Researchno datano datano data
Andrew Mulberg
Senior Vice President of Regulatory Affairsno datano datano data
Ricardo Jimenez
Senior Vice President of Technical Operationsno datano datano data
Arvind Sreedharan
Senior Vice President of Business Operationsno datano datano data
Julie Jordan
Chief Medical Officerless than a yearno datano data

1.0yrs

Average Tenure

51yo

Average Age

Experienced Management: NGNE's management team is not considered experienced ( 1 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Rachel McMinn
Founderless than a yearUS$1.08m8.75%
$ 29.4m
Robert Baffi
Independent Directorless than a yearUS$64.08k0.10%
$ 340.7k
Rohan Palekar
Independent Director2.8yrsUS$71.62k0.065%
$ 219.5k
Sarah Noonberg
Independent Director5.3yrsUS$62.12k0.073%
$ 244.4k
Cory Freedland
Independent Directorless than a yearno data0.032%
$ 106.4k
Robert Woods
Independent Directorless than a yearno data0%
$ 0

1.0yrs

Average Tenure

56yo

Average Age

Experienced Board: NGNE's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 02:09
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Neurogene Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Keith TapperBMO Capital Markets Equity Research
Mitchell KapoorH.C. Wainwright & Co.